LymphBridge™
LymphBridge™ is a clinical study that is currently enrolling 60 patients to evaluate the therapeutic benefit of using the BioBridge© Collagen Matrix as an adjunct to Lymph Node Transfer for improving the treatment of breast cancer-related lymphedema.
This multi-site study is being conducted at the University of Chicago Medicine and Stanford Medicine with funding provided by the U.S National Cancer Institute (NCI).
Enroll in the LymphBridge™ study to be part of the solution
The LymphBridge™ clinical study is open to women who are 18 to 75 years of age who are breast cancer survivors that have developed lymphedema, at least 3 years beyond completion of cancer therapy, free of clinical disease and eligible for surgical intervention. Candidates must also meet detailed inclusion and exclusion criteria as defined in the study protocol to be selected for enrolled in the study.
Learn more today
For additional information about the LymphBridge™ study, please visit clinicaltrials.gov.
